Aytu Biopharma (AYTU) Amortization of Deferred Charges (2016 - 2026)

Aytu Biopharma (AYTU) has 8 years of Amortization of Deferred Charges data on file, last reported at $27000.0 in Q1 2026.

• On a quarterly basis, Amortization of Deferred Charges changed 0.0% year-over-year to $27000.0 in Q1 2026; TTM through Mar 2026 was $111000.0, a 48.61% decrease from a year earlier, with the FY2025 full-year figure at $108000.0, down 81.91% from the prior year.
• Amortization of Deferred Charges for Q1 2026 stood at $27000.0, down from $29000.0 in the prior quarter.
• Over the last five years, Amortization of Deferred Charges for AYTU reached as high as $170000.0 in Q4 2022 and fell as low as $26000.0 in Q2 2025.
• Historically, Amortization of Deferred Charges has averaged $93588.2 across 5 years, with a median of $100000.0 in 2022.
• Across the five-year window, Amortization of Deferred Charges surged 203.03% in 2022 and slumped 83.23% in 2025, its largest moves.
• Year by year, Amortization of Deferred Charges stood at $170000.0 in 2022, then fell by 9.41% to $154000.0 in 2023, then slumped by 81.82% to $28000.0 in 2024, then rose by 3.57% to $29000.0 in 2025, then retreated by 6.9% to $27000.0 in 2026.
• Per Business Quant data, the three most recent Amortization of Deferred Charges figures were $27000.0 in Q1 2026, $29000.0 in Q4 2025, and $29000.0 in Q3 2025.